IP Library Granted Patent US 7,365,056
Granted Patent B2
US 7,365,056 · App. 10/534,628 · Granted Apr 29, 2008

Substituted 9a-N-(N′-(sulfonyl)phenylcarbamoyl)derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithomycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9-a-aza-9a-homoerithronolide A

Assignee: GlaxoSmithKline istrazivacki centar Zagreb d.o
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,365,056
App. No.
10/534,628
Granted
Apr 29, 2008
Kind
B2
Abstract

The invention relates to substituted 9a-N-{N′-[4-(sulfonyl)phenyl]carbamoyl} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-di-hydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series general formula (1), wherein R represents H or cladinosyl moiety and R1 represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-4-isoxalylamino and 5-methyl-3-isoxazolylamino group, and pharmaceutically acceptable addition salts thereof with inorganic or organic acids. to the process for their preparation of pharmaceutical composition as well as the use their compositions for sterilization rooms and medical instruments as well as for protection of wall and wooden coatings

Claims (30)

1. A compound of formula 1,

wherein R represents H or cladinosyl moiety, and R 1 represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino group, or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , characterized in that R 1 represents chloro group and R represents cladinosyl moiety.

3. A compound according to claim 1 characterized in that R 1 represents chloro group, and R represents H.

4. A compound according to claim 1 where R 1 represents amino group, and R represents cladinosyl moiety.

5. A compound according to claim 1 , characterized in that R 1 represents phenylamino group, and P represents cladinosyl group.

6. A compound according to claim 1 , characterized in that R 1 represents 2-pyridylamino group, and R represents ciadinosyl group.

7. A compound according to claim 1 , characterized in that R 1 represents 3,4-dimethyl-5-isoxazolylamino group, and R represents cladinosyl moiety.

8. A compound according to claim 1 , characterized in that R 1 represents 5-methyl-3-isoxazolylamino group, and R represents cladinosyl group.

9. A compound according to claim 1 , characterized in that R 1 represents amino group and R represents H.

10. A compound according to claim 1 , characterized in that R 1 represents phenylamino group, and R represents H.

11. A compound according to claim 1 , characterized in that R 1 represents 2-pyridylamino group, and R represents H.

12. A compound according to claim 1 , characterized in that R 1 represents 3,4-dimethyl-5-isoxazolylamino group, and R represents H.

13. A compound according to claim 1 , characterized in that R 1 represents 5-methyl-3-isoxazolylamino group and R represents H.

14. A process for the preparation of a compound of formula 1,

wherein R 1 represents amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino group and R represents H or cladinosyl group, comprising reacting a compound of formula 2

wherein R represents H or cladinosyl group, with 4-(chlorosulfonyl)phenyl isocyanate formula 3,

to form a compound of formula 1 wherein R is H or cladinosyl group and R 1 is chloro; reacting a compound of formula 1 wherein R is H or cladinosyl group and R 1 is chloro with ammonia or amine of general formula 4,

R 2 —NH 2   4

wherein R 2 represents H, phenyl, 2-pyridyl, 3,4-dimethyl-5-isoxazolyl or 5-methyl-3-isoxazolyl group, in toluene, xylene or some other aprotic solvent, at a temperature 0-110° C. to form a compound of formula 1 wherein R is H or cladinosyl and R 1 is amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino.

15. Pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibacterially effective amount of a compound according to claim 1 .

16. A method for inhibiting bacterial growth in vitro on a surface or in a substance comprising applying to said surface or substance a bactericially effective amount of a compound according to claim 1 .

17. The method of claim 16 wherein the surface is selected from the group consisting of a wall, a room, and a medical instrument.

18. The method of claim 16 wherein the substance is selected from the group of wall coatings and wooden coatings.

19. A process for the preparation of a compound of formula 1,

wherein R 1 represents chloro and R represents H or cladinosyl group, comprising reacting a compound of formula 2

wherein R represents H or cladinosyl group with 4-(chlorosulfonyl)phenyl isocyanate formula 3,

to form a compound of formula 1 wherein R is H or cladinosyl and R 1 is chloro.

20. A compound of general formula 1,

wherein R represents H or cladinosyl moiety, and R 1 represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino or 5-methyl-3-isoxazolylamino group.

Assignments (2)
CHANGE OF NAME Recorded Sep 18, 2006
From: PLIVA-ISTRAZIVACKI INSTITUT D.O.O.
To: GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O.
Reel/Frame 018260/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2005
From: KUJUNDZIC, NEDJELJKO; BUKVIC-KRAJACIC, MIRJANA; BRAJSA, KARMEN
To: PLIVA-ISTRAZIVACKI INSTITUT D.O.O.
Reel/Frame 016917/0874 →
Priority Claims (1)
HR P 20020885 A · Nov 11, 2002 · national
Continuity (1)
Related Publication 20060084795A1 · Apr 20, 2006